<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615987</url>
  </required_header>
  <id_info>
    <org_study_id>2022-01-14</org_study_id>
    <nct_id>NCT05615987</nct_id>
  </id_info>
  <brief_title>Comparison of Botulinum Toxin Injection Techniques in Spasticity</brief_title>
  <official_title>Comparison of the Efficacy of 2 Different Botulinum Toxin Injection Techniques in Gastrocnemius Muscle Spasticity in Hemiplegic Patients: A Randomized Double-blind Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konya Beyhekim Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konya Beyhekim Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effectiveness of the classical (2-4 points to the&#xD;
      muscle proximal) application of botulinum toxin in the treatment of spasticity with the&#xD;
      application along the length of the gastrecnemius muscle.&#xD;
&#xD;
      The main question it aims to answer Is botulinum toxin more effective in the treatment of&#xD;
      spasticity than the classical application applied along the length of the gastrocnemius&#xD;
      muscle? Participants will be evaluated for spasticity before and 1 month after injection.&#xD;
&#xD;
      Researchers will compare classical versus application along the length of the muscle to see&#xD;
      if there is a reduction in spasticity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spasticity assessment (change between pre-injection and 1-month control)</measure>
    <time_frame>before injection and 1 month after injection</time_frame>
    <description>Modified ashworth scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spasticity assessment (change between pre-injection and 1-month control)</measure>
    <time_frame>before injection and 1 month after injection</time_frame>
    <description>Tardieu scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spasticity assessment (change between pre-injection and 1-month control)</measure>
    <time_frame>before injection and 1 month after injection</time_frame>
    <description>Joint range of motion measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ambulation level (change between pre-injection and 1-month control)</measure>
    <time_frame>before injection and 1 month after injection</time_frame>
    <description>functional ambulation scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ambulation velocity (change between pre-injection and 1-month control)</measure>
    <time_frame>before injection and 1 month after injection</time_frame>
    <description>preferred walking speed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spastic Hemiplegia</condition>
  <arm_group>
    <arm_group_label>Classic injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200iu/2ml OnabotulinumtoxinA in total to 2-4 points proximal to the gastrocnemius muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>İnjection along the length of the muscle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 200iu/2ml of onabotulinumtoxinA by spreading along the length of the gastrocnemius muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinumtoxina for Injection</intervention_name>
    <description>200iu/2ml in both groups</description>
    <arm_group_label>Classic injection</arm_group_label>
    <arm_group_label>İnjection along the length of the muscle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with spastic hemiplegia&#xD;
&#xD;
          -  Spasticity in the gastrocnemius muscle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have spasticity in other muscles that will affect ankle movements&#xD;
&#xD;
          -  Those who use myorelaxant or myospasm-effective drugs&#xD;
&#xD;
          -  Those who have been applied botulinum toxin in the last 3 months&#xD;
&#xD;
          -  Those who have contractures in the ankle and knee due to orthopedic reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Savaş Karpuz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konya Beyhekim Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Savaş Karpuz, M.D.</last_name>
    <phone>+905552057860</phone>
    <email>svskrpz@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konya Beyhekim Research and Training Hospital</name>
      <address>
        <city>Konya</city>
        <state>Selçuklu</state>
        <zip>42060</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kim MW, Kim JH, Yang YJ, Ko YJ. Anatomic localization of motor points in gastrocnemius and soleus muscles. Am J Phys Med Rehabil. 2005 Sep;84(9):680-3. doi: 10.1097/01.phm.0000176341.85398.a9.</citation>
    <PMID>16141745</PMID>
  </reference>
  <reference>
    <citation>Prodanov D, Nagelkerke N, Marani E. Spatial clustering analysis in neuroanatomy: applications of different approaches to motor nerve fiber distribution. J Neurosci Methods. 2007 Feb 15;160(1):93-108. doi: 10.1016/j.jneumeth.2006.08.017. Epub 2006 Oct 17.</citation>
    <PMID>17049615</PMID>
  </reference>
  <reference>
    <citation>Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993 Sep;16(9):964-9. doi: 10.1002/mus.880160913.</citation>
    <PMID>8355728</PMID>
  </reference>
  <reference>
    <citation>Prodanov D, Thil MA, Marani E, Delbeke J, Holsheimer J. Three-dimensional topography of the motor endplates of the rat gastrocnemius muscle. Muscle Nerve. 2005 Sep;32(3):292-302. doi: 10.1002/mus.20378.</citation>
    <PMID>15948200</PMID>
  </reference>
  <reference>
    <citation>Childers MK, Kornegay JN, Aoki R, Otaviani L, Bogan DJ, Petroski G. Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve. 1998 May;21(5):653-5. doi: 10.1002/(sici)1097-4598(199805)21:53.0.co;2-w.</citation>
    <PMID>9572248</PMID>
  </reference>
  <reference>
    <citation>Kaymak B, Kara M, Tok F, Ulasli AM, Ozturk GT, Chang KV, Hsiao MY, Hung CY, Yagiz On A, Ozcakar L. Sonographic guide for botulinum toxin injections of the lower limb: EUROMUSCULUS/USPRM spasticity approach. Eur J Phys Rehabil Med. 2018 Jun;54(3):486-498. doi: 10.23736/S1973-9087.17.04667-6. Epub 2017 Apr 4.</citation>
    <PMID>28382814</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konya Beyhekim Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Savaş Karpuz</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemiplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shared if requested.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

